About: Intermittent androgen suppression in the management of prostate cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intermittent androgen suppression in the management of prostate cancer Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 March 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в березні 1999 (uk) im März 1999 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en marzu de 1999 (ast) scientific article published on 01 March 1999 (en)
publication date	wds:Q74650210-082F775B-1A06-4154-84B0-CB1147BDD3DA
publication date	1999-03-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q74650210-F4947EFC-245F-4457-B2AD-4DDAC599FF6B
language of work or name	English
cites work	wds:Q74650210-3FDCF57D-EDD3-4055-80B1-2054E7FC8491 wds:Q74650210-510CB4AD-4AC8-4B36-B728-0D688762A7EA wds:Q74650210-5955B569-1D8A-4150-968B-3DABCFA65474 wds:Q74650210-65214411-9438-4537-A75D-1A7FB3482CFE wds:Q74650210-70CCD2D9-5E87-47F7-BDCB-A1F51082E66B wds:Q74650210-7124CDBC-A187-4919-BFC2-BD4A4AFFC9DD wds:Q74650210-9193B809-1FCC-4E10-A8C3-1DF03F56EE35 wds:Q74650210-9B9AB164-6BDF-4465-B248-475987782844 wds:Q74650210-9C688DE9-246A-402D-8872-3969413EB1F0 wds:Q74650210-B99FFFE4-88FA-45B5-BF9A-F278587B4222 wds:Q74650210-FDD0FDA4-B11C-437A-A894-6520338D5A1B
cites work	Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial A controlled trial of leuprolide with and without flutamide in prostatic carcinoma Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen Intermittent endocrine therapy for advanced prostate cancer Treatment of clinical local failure after radiation therapy for prostate carcinoma New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation
author name string	wds:Q74650210-004B7799-0768-4375-9041-5FF5C06D080F wds:Q74650210-1D836934-B2CA-4CDC-BA1E-B775F45E3E2F wds:Q74650210-9EC3437A-8E13-45FE-A344-60C6D1FA519C wds:Q74650210-E80CFB43-FB6B-44E3-8E76-2524118AB45E wds:Q74650210-FE3CAF48-CEAD-492F-B77D-1F6CDB231399
author name string	R Segal S Malone J M Crook E Szumacher S Huan
rdfs:label	Intermittent androgen suppression in the management of prostate cancer (en) Intermittent androgen suppression in the management of prostate cancer (nl)
skos:prefLabel	Intermittent androgen suppression in the management of prostate cancer (en) Intermittent androgen suppression in the management of prostate cancer (nl)
name	Intermittent androgen suppression in the management of prostate cancer (en) Intermittent androgen suppression in the management of prostate cancer (nl)
title	wds:Q74650210-86A81968-E594-47CF-9477-664C062B6FF2
title	Intermittent androgen suppression in the management of prostate cancer (en)
page(s)	wds:Q74650210-94B1B199-8928-448C-B6C1-909A944BB4D2
page(s)	530-534
instance of	wds:Q74650210-9EE1D029-7113-4588-9734-5C458C997409
instance of	scholarly article
main subject	wds:Q74650210-3B50948F-A527-4C6C-A950-33DF5E06FF95
main subject	prostate cancer
PubMed ID	wds:Q74650210-DE93F7A6-864A-4F54-95C5-F46C1FF1C632
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10096379
PubMed ID	10096379
published in	wds:Q74650210-A374DF7D-6EE0-4A84-93D4-AD4A1AEDA8AA
published in	Urology
issue	wds:Q74650210-39DDE952-4368-4562-AC7B-ECBB00BFC0BE
volume	wds:Q74650210-4F3E04A1-24E3-45F0-8982-328F76ED426D
issue	3
volume	53
DOI	wds:Q74650210-EC4CCF77-E369-4D94-B925-F23ADF7E02D1
DOI	http://dx.doi.org/10.1016/S0090-4295(98)00547-0
DOI	10.1016/S0090-4295(98)00547-0
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q74650210
is cites work of	Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer Intermittent androgen suppression for rising PSA level after radiotherapy Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer Intermittent androgen deprivation: clinical experience and practical applications The androgen receptor: structure, mutations, and antiandrogens Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments Prostate cancer management: 2. An update on locally advanced and metastatic disease Intermittent androgen deprivation Intermittent androgen suppression in prostate cancer: the Canadian experience Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer Intermittent androgen suppression A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Intermittent versus continuous androgen suppression for prostatic cancer Treatments for improving survival of patients with prostate cancer 5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models Androgen suppression strategies for prostate cancer: is there an ideal approach? Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride. Intermittent Androgen Deprivation for Patients With Recurrent/Metastatic Prostate Cancer Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters Conventional treatments of localized prostate cancer. 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. Challenges of managing elderly men with prostate cancer Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience Intermittent versus continuous androgen suppression for prostatic cancer Hormonal therapy for prostate cancer Patient-Clinician choice in palliation of metastatic prostate cancer Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 109 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software